PHASE II CLINICAL PROTOCOL FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA WITH A COMBINATION OF BENDAMUSTINE AND OFATUMUMAB
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall Response Rate (Efficacy)
The primary objective for this study is to evaluate the overall response rate of bendamustine and ofatumumab in patients with previously untreated CLL.
No
Mark Kirschbaum, MD
Principal Investigator
Nevada Cancer Institute
United States: Food and Drug Administration
NVCI 09-14
NCT01125787
May 2010
April 2011
Name | Location |
---|---|
University of Florida | Gainesville, Florida 32610-0277 |
Nevada Cancer Institute | Las Vegas, Nevada 89135 |